SCYX - SCYNEXIS, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.05
-0.00 (-0.31%)
As of 2:17PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.05
Open1.05
Bid1.04 x 900
Ask1.05 x 1000
Day's Range1.04 - 1.07
52 Week Range1.04 - 2.45
Volume235,340
Avg. Volume285,746
Market Cap49.209M
Beta (3Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.81
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

    JERSEY CITY, N.J., Oct. 15, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the dosing of the first patient with a Candida auris infection, an emerging life-threatening and multidrug-resistant fungal pathogen, in a Phase 3 open-label study evaluating oral ibrexafungerp (formerly SCY-078) in patients with candidiasis caused by C. auris (the CARES Study). Ibrexafungerp, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.

  • PR Newswire18 days ago

    SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week

    -- HHS and CDC Lead Efforts Aim to Combat Antimicrobial Resistance, Raise Awareness of Fungal Diseases -- JERSEY CITY, N.J. , Oct. 1, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX), a biotechnology ...

  • PR Newswire23 days ago

    SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018

    JERSEY CITY, N.J. , Sept. 26, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...

  • PR Newswire24 days ago

    SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

    JERSEY CITY, N.J. , Sept. 25, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...

  • Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?
    Simply Wall St.last month

    Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?

    A look at the shareholders of SCYNEXIS Inc (NASDAQ:SCYX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to seeRead More...

  • 5 Healthcare Stocks That Are Down, But Not Out!
    InvestorPlace2 months ago

    5 Healthcare Stocks That Are Down, But Not Out!

    Few investment sectors arouse sharply divided opinion quite like healthcare stocks. This segment features incredible volatility as poor clinical trials could devastate individual companies. During the campaign trail for the 2016 presidential election, then-real-estate-mogul Donald Trump lashed out against pharmaceuticals.

  • PR Newswire2 months ago

    SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

    JERSEY CITY, N.J. , Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...

  • Scynexis (SCYX) Reports Q2 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Scynexis (SCYX) Reports Q2 Loss, Lags Revenue Estimates

    Scynexis (SCYX) delivered earnings and revenue surprises of -64.29% and -20.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Scynexis: 2Q Earnings Snapshot

    On a per-share basis, the Jersey City, New Jersey-based company said it had a loss of 23 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • PR Newswire2 months ago

    SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update

    ­­Oral dose regimen of ibrexafungerp (formerly SCY-078) identified for Phase 3 VVC development; Phase 3 on track for initiation in the fourth quarter of 2018 Development of ibrexafungerp intravenous (IV) ...

  • ACCESSWIRE3 months ago

    Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks

    Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX).

  • PR Newswire3 months ago

    The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078

    New WHO INN stem "-fungerp" signifies a novel class of antifungals Novel generic name highlights the unique attributes of SCY-078 and its potential to address significant unmet needs across multiple ...

  • Why Scynexis Stock Rose 16.4% Yesterday
    Market Realist3 months ago

    Why Scynexis Stock Rose 16.4% Yesterday

    Yesterday, Scynexis (SCYX) stock rose 16.4% on the announcement of positive data from its Phase 2b clinical trial of its drug candidate SCY-078 for the treatment of VVC (vulvovaginal candidiasis), or vaginal yeast infection. The findings were compared to treatment results for the standard of care drug Flu (fluconazole). Currently, the SCY-078 candidate is also being developed and evaluated for the treatment of a number of other serious fungal infections, including invasive candidiasis, invasive aspergillosis, and refractory invasive fungal infections. Currently, the only approved oral drug for the treatment of VVC is fluconazole, whereas there are no approved products for patients with recurrent VVC.

  • PR Newswire3 months ago

    SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

    Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program Results confirm strong clinical activity of oral SCY-078 and suggest improved ...

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks

    Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.

  • PR Newswire4 months ago

    SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting

    JERSEY CITY, N.J., June 27, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the presentation of data at the Teratology Society 58th Annual Meeting, June 23-27, 2018 in Clearwater, Florida. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. "The treatment of fungal infections during pregnancy has long been challenging due to the well-known developmental toxicities associated with existing antifungal treatments," said David Angulo, M.D., Chief Medical Officer of SCYNEXIS.

  • PR Newswire4 months ago

    SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018

    20th International Symposium on Infections in the Immunocompromised Host (ICHS) Teratology Society 58th Annual Meeting 20th Congress of the International Society for Human and Animal Mycology (ISHAM) JERSEY ...

  • PR Newswire4 months ago

    SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018

    SCY-078 demonstrates potent in vitro activity vs. echinocandin-resistant Candida strains and synergistic activity with isavuconazole vs. Aspergillus spp. SCY-078 exhibits a profound effect on cellular ...

  • PR Newswire4 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • PR Newswire4 months ago

    SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology

    JERSEY CITY, N.J., June 6, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the publication of results from a Phase 1 study of SCY-078, assessing the risk for drug-drug interactions when administered with drugs metabolized by the CYP family of enzymes, in The Journal of Clinical Pharmacology.  SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. The article, "Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions," describes the Phase 1 study, in which the pharmacokinetic parameters of rosiglitazone, a thiazolidinedione agent commonly used for type 2 diabetes, were measured in the absence and presence of SCY-078 dosed to therapeutically relevant levels in healthy adult subjects.

  • PR Newswire5 months ago

    SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018

    JERSEY CITY, N.J. , May 24, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...

  • ACCESSWIRE5 months ago

    Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks

    Pre-market, WallStEquities.com takes a look at the recent performance of Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). On Wednesday, shares in Canonsburg, Pennsylvania headquartered Mylan N.V. recorded a trading volume of 3.81 million shares.

  • PR Newswire5 months ago

    SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention

    JERSEY CITY, N.J. , May 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...

  • What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?
    Market Realist5 months ago

    What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?

    SCYNEXIS (SCYX) witnessed a 28% rise in its stock price in the week ended May 18. On May 18, SCYNEXIS stock closed at $1.63, which is ~14.4% growth from its previous close of $1.43 on May 17. SCYNEXIS stock rose ~27% over the last month. SCYNEXIS is a biotechnology company focused on the development of innovative therapies for the treatment of patients with difficult-to-treat and life-threatening infections.

  • Associated Press5 months ago

    Scynexis: 1Q Earnings Snapshot

    The Jersey City, New Jersey-based company said it had a loss of 12 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...